Fluticasone Propionate
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) has cancelled the presolicitation for a national requirements contract for Fluticasone Propionate (various dosages). This action, announced via Amendment 0001 to solicitation SPE2D225R0015, nullifies all previous intentions and requirements related to this opportunity.
Scope of Change
This amendment cancels the entire solicitation SPE2D225R0015 in its entirety. The original intent was to procure Fluticasone Propionate 115 MCG, 230 MCG, and 45 MCG with Salmeterol 21 MCG/Actuation HFA Inhalers for Department of Defense, Indian Health Service, and Bureau of Prisons customers.
Contract & Timeline
- Original Opportunity Type: Presolicitation
- Original Projected Solicitation Date: May 2025
- Cancellation Date: March 3, 2026 (as per amendment posting)
- Set-Aside: Unrestricted (originally planned)
Additional Notes
All previous deadlines and submission requirements for this presolicitation are now nullified. Interested parties should note that this opportunity is no longer active. The DLA reserves the right to issue a new solicitation for these items in the future.